person · Reporting owner
Fitzgerald Joseph Michael
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | EVP & Group Pres, Cardiology | July 31, 2026 | August 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date July 31, 2026 · Filed August 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) | 64,198 |
Reported balance
After 2026-07-31 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-07-31 · Other · Acquired 64,198 · Balance 64,198 F1: Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock. F2: Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan. |
| Common StockSEC Table I · non-derivative | Direct | 213,907 |
Reported balance
Holding disclosure · report date 2026-07-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 213,907 |
| Common StockSEC Table I · non-derivative | IndirectBy Child | 5,234 |
Reported balance
Holding disclosure · report date 2026-07-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 5,234 F3: The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock.
F2: Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.
F3: The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 21, 2020 Filed Feb 24, 2020 22:09 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 3,894 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003287 · doc4.xml · derivative · entry 10 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,684 Underlying: Common Stock · 3,894 shares Expires 2023-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:09 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,922 | $42.62 | $81,915.64 |
DisclosureSEC source: 0001225208-20-003287 · doc4.xml · nonDerivative · entry 3 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,074 Read SEC document |
| February 21, 2020 Filed Feb 24, 2020 22:09 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 3,894 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003287 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 19, 2020 Filed Feb 24, 2020 22:09 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 10,949 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-003287 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,102 Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:30 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 55,309 | $0.00 Strike: $42.16 | $0.00 |
DisclosureSEC source: 0001225208-20-002835 · doc4.xml · derivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,309 Underlying: Common Stock · 55,309 shares Expires 2030-02-18 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 22:30 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantDeferred Stock Units · Derivative | 14,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002835 · doc4.xml · derivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,824 Underlying: Common Stock · 14,824 shares Expires 2024-02-18 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 4,614 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002605 · doc4.xml · derivative · entry 9 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,843 Underlying: Common Stock · 4,614 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F6 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F6 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 2,278 | $42.31 | $96,382.18 |
DisclosureSEC source: 0001225208-20-002605 · doc4.xml · nonDerivative · entry 6 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,051 Read SEC document |
| February 15, 2020 Filed Feb 18, 2020 21:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,614 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002605 · doc4.xml · nonDerivative · entry 5 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 21:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 14,669 | $42.31 | $620,645.39 |
DisclosureSEC source: 0001225208-20-002605 · doc4.xml · nonDerivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,715 Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 21:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 29,723 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002605 · doc4.xml · nonDerivative · entry 3 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,384 F2 · shares: On March 3, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2019 and subject to the completion of the concurrent three-year individual service period. On February 14, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| February 07, 2020 Filed Feb 18, 2020 21:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 2,085 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002605 · doc4.xml · nonDerivative · entry 7 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Indirect · By Children Disclosed balance after: 6,777 F1 · kind: This transaction involved a gift of securities by the reporting person to his children, who share reporting person's household. F4 · balance_after: Balance reflects gifts made in 2018, 2019, and 2020 to certain of the reporting person's children that, as of the date of this report, share his household. The reporting person disclaims beneficial ownership of the shares held by his children, and this report should not be deemed an admission that the reporting person is the beneficial owner of his children's shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 07, 2020 Filed Feb 18, 2020 21:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 2,085 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002605 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,661 F1 · kind: This transaction involved a gift of securities by the reporting person to his children, who share reporting person's household. Read SEC document |
| February 07, 2020 Filed Feb 18, 2020 21:10 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 695 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002605 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,746 Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 21:19 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 17,582 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-000294 · doc4.xml · derivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,582 shares Expires 2019-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The Performance Share Units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2019. F1 · derivative.exercise_date: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The Performance Share Units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2019. F1 · derivative.expiration_date: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The Performance Share Units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2019. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 21:19 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 8,826 | $45.22 | $399,111.72 |
DisclosureSEC source: 0001225208-20-000294 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,441 Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 21:19 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 17,582 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-000294 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,267 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The Performance Share Units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2019. Read SEC document |
| December 13, 2019 Filed Dec 16, 2019 21:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 107,692 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0001225208-19-015842 · doc4.xml · derivative · entry 5 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 107,692 shares Expires 2020-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2011, the first anniversary of the grant. Read SEC document |
| December 13, 2019 Filed Dec 16, 2019 21:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 107,692 | $45.00 | $4,846,140.00 |
DisclosureSEC source: 0001225208-19-015842 · doc4.xml · nonDerivative · entry 3 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,685 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| December 13, 2019 Filed Dec 16, 2019 21:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 107,692 | $7.41 | $797,997.72 |
DisclosureSEC source: 0001225208-19-015842 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| July 30, 2019 Filed Dec 16, 2019 21:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 3,571 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-015842 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,685 Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 20:07 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 20,673 | $43.41 | $897,414.93 |
DisclosureSEC source: 0001225208-19-009819 · doc4.xml · nonDerivative · entry 3 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,256 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| June 28, 2019 Filed Jul 2, 2019 20:07 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 1,906 | $43.00 | $81,958.00 |
DisclosureSEC source: 0001225208-19-009819 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,929 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| May 02, 2019 Filed Jul 2, 2019 20:07 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 1,033 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-009819 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,835 Read SEC document |
| March 03, 2019 Filed Mar 4, 2019 21:31 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 3,603 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004345 · doc4.xml · derivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,809 Underlying: Common Stock · 3,603 shares Expires 2022-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant. Read SEC document |
| March 03, 2019 Filed Mar 4, 2019 21:31 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,643 | $40.75 | $66,952.25 |
DisclosureSEC source: 0001225208-19-004345 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,868 Read SEC document |
| March 03, 2019 Filed Mar 4, 2019 21:31 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 3,603 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-004345 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,511 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 24, 2019 Filed Feb 26, 2019 21:34 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 4,779 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003725 · doc4.xml · derivative · entry 10 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,779 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| February 24, 2019 Filed Feb 26, 2019 21:34 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 2,180 | $40.52 | $88,333.60 |
DisclosureSEC source: 0001225208-19-003725 · doc4.xml · nonDerivative · entry 6 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,908 Read SEC document |
| February 24, 2019 Filed Feb 26, 2019 21:34 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,779 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003725 · doc4.xml · nonDerivative · entry 5 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 23, 2019 Filed Feb 26, 2019 21:34 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 4,139 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003725 · doc4.xml · derivative · entry 9 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,139 Underlying: Common Stock · 4,139 shares Expires 2020-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Read SEC document |
| February 23, 2019 Filed Feb 26, 2019 21:34 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,888 | $40.52 | $76,501.76 |
DisclosureSEC source: 0001225208-19-003725 · doc4.xml · nonDerivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,309 Read SEC document |
| February 23, 2019 Filed Feb 26, 2019 21:34 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,139 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003725 · doc4.xml · nonDerivative · entry 3 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,197 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 21:34 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 4,056 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003725 · doc4.xml · derivative · entry 8 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,112 Underlying: Common Stock · 4,056 shares Expires 2021-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 21:34 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,850 | $40.52 | $74,962.00 |
DisclosureSEC source: 0001225208-19-003725 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,058 Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 21:34 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,056 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003725 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,908 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:37 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 50,443 | $0.00 Strike: $40.12 | $0.00 |
DisclosureSEC source: 0001225208-19-003564 · doc4.xml · derivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,443 Underlying: Common Stock · 50,443 shares Expires 2029-02-21 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 23:37 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantDeferred Stock Units · Derivative | 15,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003564 · doc4.xml · derivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,578 Underlying: Common Stock · 15,578 shares Expires 2023-02-21 F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 23:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantPerformance Share Units · Derivative | 27,199 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003438 · doc4.xml · derivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,199 Underlying: Common Stock · 27,199 shares Expires 2020-12-31 F3 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · shares: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2020. F4 · derivative.exercise_date: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2020. F4 · derivative.expiration_date: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2020. F4 · balance_after: On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2020. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 23:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 18,494 | $40.11 | $741,794.34 |
DisclosureSEC source: 0001225208-19-003438 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,852 Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 23:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 40,556 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-003438 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,346 F1 · shares: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2018 and subject to the completion of the concurrent three-year individual service period. On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 23:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 4,614 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002982 · doc4.xml · derivative · entry 6 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,457 Underlying: Common Stock · 4,614 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 23:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 2,104 | $40.01 | $84,181.04 |
DisclosureSEC source: 0001225208-19-002982 · doc4.xml · nonDerivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,790 Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 23:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,614 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002982 · doc4.xml · nonDerivative · entry 3 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 23:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 660 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002982 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,280 Read SEC document |
| February 13, 2019 Filed Feb 19, 2019 23:15 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-002982 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,940 Read SEC document |
| February 12, 2019 Filed Feb 13, 2019 21:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 44,236 | $0.00 Strike: $8.30 | $0.00 |
DisclosureSEC source: 0001225208-19-002436 · doc4.xml · derivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,236 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of common stock vesting in four annual increments beginning on February 24, 2010, the first anniversary of the grant. Read SEC document |
| February 12, 2019 Filed Feb 13, 2019 21:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 44,236 | $40.00 | $1,769,440.00 |
DisclosureSEC source: 0001225208-19-002436 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,940 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| February 12, 2019 Filed Feb 13, 2019 21:12 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 44,236 | $8.30 | $367,158.80 |
DisclosureSEC source: 0001225208-19-002436 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 21:55 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 23,157 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-000436 · doc4.xml · derivative · entry 6 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,157 shares Expires 2018-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ends on December 31, 2018. F1 · derivative.exercise_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ends on December 31, 2018. F1 · derivative.expiration_date: On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ends on December 31, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.